Aurinia Pharmaceuticals - Common Shares (AUPH) closed at $16.56 on November 3, 2026, up 2.6% from the previous close, on volume of 1,125,123 shares (30-day average 772,159).
Data as of November 3, 2026.
Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)
TipRanks (Tue, 3-Nov 5:10 AM ET)
RBC Capital Gives a Hold Rating to Aurinia Pharmaceuticals (AUPH)
TipRanks (Mon, 2-Nov 10:28 AM ET)
Aurinia lifts 2026 guidance as LUPKYNIS growth, cash flow and pipeline momentum build
TipRanks (Fri, 30-Oct 11:41 AM ET)
Aurinia Revenue Rises on Strong LUPKYNIS Sales and Partner Income
TipRanks (Fri, 30-Oct 11:40 AM ET)
Aurinia Pharma GAAP EPS of $0.23 beats by $0.01, revenue of $83.7M beats by $0.09M
Seeking Alpha News (Fri, 30-Oct 8:06 AM ET)
Business Wire (Fri, 30-Oct 8:00 AM ET)
Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036
Market Chameleon (Thu, 20-Aug 5:42 AM ET)
Aurinia Settles Patent Litigation with Teva
Business Wire (Wed, 19-Aug 4:05 PM ET)
Business Wire (Thu, 6-Aug 8:00 AM ET)
Tang Capital Boosts Stake in Aurinia Pharmaceuticals—Owns 10% After $3.1 Million Stock Purchase
Market Chameleon (Thu, 4-Jun 7:49 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of November 4, 2026, AUPH stock price climbed to $16.65 with 77,125 million shares trading.
AUPH has a beta of 0.05, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.
AUPH has a market cap of $2.23 billion. This is considered a Mid Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $84 million in Revenue and $.23 earnings per share. This fell short of revenue expectation by $-627,264 and exceeded earnings estimates by $.01.
In the last 3 years, AUPH traded as high as $19.25 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
AUPH has outperformed the market in the last year with a return of +26.4%, while the SPY ETF gained +13.5%. In the last 3 month period, AUPH beat the market returning +14.3%, while SPY returned +1.6%. However, in the most recent 2 weeks AUPH has underperformed the stock market by returning -0.5%, while SPY returned -0.2%.
AUPH support price is $16.25 and resistance is $16.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.
